Background {#Sec1}
==========

Cardiovascular diseases (CVDs) remain one of the most prevalent non-communicable diseases and impose a great burden on the healthcare systems. Globally, an estimated 16.7 million deaths in the year 2010 were attributed to CVD with projections showing a staggering 23.3 million deaths by 2030 \[[@CR1]\]. Hypertension is the leading risk factor for CVD and it is associated with 57 million disability adjusted life years (DALYs) worldwide \[[@CR2]\].

It is well known that the risk of major cardiovascular events can be reduced by a wide spectrum of antihypertensive drugs including angiotensin receptor blockers (ARBs) \[[@CR3]\]. This type of drug works by inhibiting the angiotensin II receptors, thus causing systemic vasodilatation, thereby aiding in the reduction of blood pressure \[[@CR4]\]. ARBs are one of the most common drugs used for controlling blood pressure, treating heart failure, and preventing kidney failure in people with diabetes or hypertension \[[@CR5]\]. However, the safety of ARBs in comparison to other anti-hypertensive medications has been called into question.

The VALUE trial found that ARBs (valsartan) increased the risk of myocardial infarction (fatal and non-fatal) by 19% compared with calcium channel blockers (amlodipine) \[[@CR6]\]. This observation led many researchers to examine cautiously the evidence surrounding ARBs and myocardial infarction. For example, the point estimate of the CHARM-alternative trial suggests a 36% increase in myocardial infarction with candesartan (versus placebo) regardless of the reduction in blood pressure \[[@CR7]\]. On the other hand, the TRANSCEND trial found an 8% decrease in risk of cardiovascular admissions for those on telmisartan compared to placebo \[[@CR8]\].

Angiotensin-converting-enzyme (ACE) inhibitors are known to have a cardioprotective effect and the safety profile of ACE inhibitors have been shown not to differ from ARBs \[[@CR9]\]. Hence it was unclear the mechanism that could explain an increase in risk of myocardial infarction with ARBs. Due to the wide use of ARBs for many CVDs and the contradictory results, we decided to conduct a systematic review and meta-analysis of randomised controlled trials (RCTs) to elucidate the cardiovascular safety profile of ARBs.

Methods {#Sec2}
=======

Findings of this systematic review and meta-analysis are presented according to PRISMA reporting guidelines \[[@CR10]\].

Search strategy and selection criteria {#Sec3}
--------------------------------------

A systematic search was conducted in PubMed in September 2018. The following search terms were included: randomized controlled trial, angiotensin receptor antagonist, cardiovascular disease, and mortality. The full search strategy is shown in the [supplementary material (S1)](#MOESM1){ref-type="media"}. To achieve a comprehensive evaluation of the published evidence, the systematic search was supplemented with a similarity search (i.e. the first 20 related citations of each included paper) as well as hand search of the reference lists of relevant studies. Titles and abstracts were uploaded on Rayyan (<http://rayyan.qcri.org/>) \[[@CR11]\] for the screening process. Two authors (YW and RB) independently screened all the records by title and abstract. Disagreements were resolved through author consensus and involvement of a third author (LFK).

The inclusion of studies was restricted to human studies; RCTs comparing ARBs versus a control (either a placebo or another antihypertensive medication); follow-up of at least 12 months; and reported all-cause mortality, myocardial infarction, and stroke as outcomes. Recurrent myocardial infarction and stroke were also considered if the study only included patients that have had recently experienced myocardial infarction or stroke. Observational studies, studies where ARBs were not the first line of treatment, and conference abstracts were excluded.

Data extraction and quality assessment {#Sec4}
--------------------------------------

The number of participants and the number events (i.e. all-cause mortality, myocardial infarction, and stroke) in each intervention group (ARBs \[active\] and non-ARBs \[control\]) were extracted. In addition, study characteristics (e.g. study sites and follow-up period) and participants' characteristics (e.g. mean age, proportion of males, mean BMI) were extracted. The Cochrane Collaboration's tool for assessing risk of bias in randomized trials \[[@CR12]\] was used to assess the risk of bias of the included studies.

Statistical analysis {#Sec5}
--------------------

The outcomes of interest were the relative risks (RRs) of all-cause mortality, myocardial infarction, and stroke with ARBs compared to the control group. The inverse variance heterogeneity (IVhet) model was used to pool the effect size \[[@CR13]\]. The *I*^*2*^ index was used to assess heterogeneity among studies, an *I*^*2*^ \> 50% was considered significant heterogeneity.

Sensitivity analyses were conducted to identify potential scenarios where ARBs increase the risk of all-cause mortality, myocardial infarction, and stroke. The following analyses restricting the meta-analysis to: control group (active medication, only ACE inhibitors, or placebo); follow-up period (≤40 weeks or \> 40 weeks); proportion of males (≤50% or \> 50%); age (≤65 years or \> 65 years); BMI (normal range or overweight/obese); elevated total cholesterol (≥200 mg/dL); elevated LDL (≥120 mg/dL); decreased HDL (\< 50 mg/dL); elevated triglyceride (≥150 mg/dL); proportion of smokers (\< 25% or ≥ 25%); only patients with hypertension; only patients with or without chronic heart failure; only patients with or without diabetes mellitus; only patients with ischemic/coronary artery disease; and only patients with chronic kidney disease.

Publication bias was assessed through visual inspection of funnel and Doi plots and statistically through the Egger's regression *p*-value and the LFK index \[[@CR14]\]. All the analyses were conducted in Stata MP 14 (StataCorp, College Station, TX, USA).

Result {#Sec6}
======

Study selection and study characteristics {#Sec7}
-----------------------------------------

One thousand seven hundred and eighty-six unique records were identified through the search strategy and the similarity search. Four hundred and seventy-four records remained after the title and abstract screening and 44 publications remained after the full-text screening. The 44 publications reported data from 45 RCTs and 170,794 participants (85,544 participants in the ARB group and 85,250 participants in the placebo/control group) (Fig. [1](#Fig1){ref-type="fig"}). The publication by Chaturvedi et al. \[[@CR15]\] reported findings from two RCTs, the DIRECT-Prevent 1 and DIRECT-Protect 1 studies. Fig. 1PRISMA flow diagram of study selection

Twenty four RCTs compared ARBs versus placebo, while 21 RCTs against an active medication. The majority of RCTs (*n* = 39) included a larger proportion of males (ranging from 54 to 90%). Only two RCTs, DIRECT-Prevent 1 and DIRECT-Protect 1 enrolled participants with a median age \< 50 years. Among the studies that reported the median BMI, only 22% had participants with a normal BMI (\< 25 kg/cm^2^). Fourteen, nine, and eight RCTs included only patients with hypertension, chronic heart failure, and diabetes mellitus, respectively (Table [1](#Tab1){ref-type="table"}). All-cause mortality, myocardial infarction, and stroke were assessed in 39, 37, and 36 RCTs. Table 1Characteristics of the RCTs included in the meta-analysisTrial name, year publicationPopulationSettingInterventionControlFollow up (in months)Male (%)Mean / median age (years)Mean BMI (kg/m^2^)Mean cholesterol (mg/dL)Mean LDL (mg/dL)Mean HDL (mg/dL)Mean triglyceride (mg/dL)Non-smoker (%)Hypertension (%)Heart failure (%)Diabetes mellitus (%)Ischaemic / coronary artery disease (%)Chronic kidney disease (%)4C (2016) \[[@CR16]\]Patients with IHD after coronary stent implantation39 centres in JapanCandesartanStandard care without ARB36736924NR111491408373835100NRACTIVE I (2011) \[[@CR17]\]Patients with atrial fibrillation600 centres worldwideIrbesartanPlacebo54617029NRNRNRNR50883220NRNRCARP (2011) \[[@CR18]\]Patients that received a coronary stent5 centres in Hiroshima, JapanValsartanNon-ARB therapy48796524NRNRNRNR5075NR4310030CASE-J (2008) \[[@CR19]\]Patients with high-risk hypertension527 physicians from JapanCandesartanAmlodipine41556425NRNRNRNR791000434324CHARM-Added (2003) \[[@CR20]\]Patients with CHF and LVEF\< 40618 centres in 26 countriesCandesartanPlacebo41796428NRNRNRNR83481003068NRCHARM-Alternative (2003) \[[@CR7]\]Patients with symptomatic CHF and LVEF\< 40%618 centres in 26 countriesCandesartanPlacebo34686728NRNRNRNR86501002762NRCHARM-Preserved (2003) \[[@CR21]\]Patients with HF and LVEF\> 40618 centres in 26 countriesCandesartanPlacebo37606729NRNRNRNR87641002856NRCice et al. (2010) \[[@CR22]\]Patients with CHF and in haemodialysis30 clinics in ItalyTelmisartanPlacebo369063NRNRNRNRNR61NR1002957100DETAIL (2004) \[[@CR23]\]Patients with diabetes mellitus and nephropathy39 centres in northern EuropeTelmisartanEnalapril6073613122313748207371000100NR100DIRECT-Prevent 1 (2008) \[[@CR15]\]Patients with type 1 diabetes a no retinopathy309 centres worldwideCandesartanPlacebo56563024184NR66NR74NRNR100NR0DIRECT-Protect 1 (2008) \[[@CR15]\]Patients with type 1 diabetes and retinopathy309 centres worldwideCandesartanPlacebo56573225186NR66NR74NRNR100NR0DIRECT-Protect 2 (2008) \[[@CR24]\]Patients with type 2 diabetes and retinopathy309 centres worldwideCandesartanPlacebo56505729205NRNRNR7362NR10050E-COST (2005) \[[@CR25]\]Patients with hypertensionCentres in Saitama, JapanCandesartanNon-ARB therapy3748NRNRNRNRNRNRNR100000NRE-COST-R (2005) \[[@CR26]\]Patients with hypertension and mild renal impairmentCentres in Saitama, JapanCandesartanNon-ARB therapy375967NR181NRNRNRNR100006100ELITE (1997) \[[@CR27]\]Patients with CHF and LVEF\< 40%125 centres in the USA, Europe, and South AmericaLosartanCaptopril136774NRNRNRNRNR885710025507ELITE II (2000) \[[@CR28]\]Patients with CHF and LVEF\< 40%289 centres in 46 countriesLosartanCaptopril236971NRNRNRNRNRNR491002479NRGISSI-AF (2009) \[[@CR29]\]Patients with history of atrial fibrillation100 centres in ItalyValsartanPlacebo12626828NRNRNRNR8185815123HIJ-CREATE (2009) \[[@CR30]\]Patients with coronary artery disease and hypertension14 centres in JapanCandesartanNon-ARB therapy50806625193NR45128641002138100NRHOPE-3 (2016) \[[@CR31]\]Patients with intermediate cardiovascular risk228 centres in 21 countriesCandesartan + hydrochlorothiazidePlacebo6754662720112845128723805.800IDNT (2003) \[[@CR32]\]Patients with diabetes mellitus and nephropathyCentres in the North America, Europe, Latin America, South East Asia, and OceaniaIrbesartanAmlodipine or placebo^a^31645931NRNRNRNRNR100010028100I-PRESERVE (2008) \[[@CR33]\]Patients with CHF and LVEF \> 45%Centres in 25 countriesIrbesartanPlacebo50407230NRNRNRNRNR891002800IRMA-2 (2001) \[[@CR34]\]Patients with hypertension, diabetes mellitus, and micro-albuminuria96 centres worldwideIrbesartan^b^Placebo246958302241404418081100NR10060J-RHYTHM II (2011) \[[@CR35]\]Patients with hypertension and atrial fibrillation48 centres in JapanCandesartanAmlodipine126966NRNRNRNRNRNR100391NRKondo et al. (2003) \[[@CR36]\]Patients with history of coronary interventionOgaki Municipal Hospital in JapanStandard care + CandesartanStandard care without candesartan24766524187114491267644225100NRKYOTO HEART (2009) \[[@CR37]\]Patients with uncontrolled hypertension31 centres from Kyoto, JapanValsartanNon-ARB therapy39576639NR122551497810072723NRLIFE (2002) \[[@CR38]\]Patients with hypertension and left ventricular hypertrophy830 centres from the USA, the UK, and ScandinaviaLosartanAtenolol58466728232NR58NR8410001316NRMOSES (2005) \[[@CR39]\]High-risk hypertensive patientsCentres in Germany and AustriaEprosartanNitredipine45546828NRNRNRNRNR1002637265.4NAVIGATOR (2010) \[[@CR40]\]Patients with impaired glucose tolerance806 centres in 40 countriesValsartanPlacebo60496431210127501518978NR491211OCTOPUS (2013) \[[@CR41]\]Patients with hypertension and in haemodialysis66 dialysis centres in Okinawa, JapanOlmesartanNon-ARB therapy60626024155NRNR15565100NR327100ONTARGET (2008) \[[@CR42]\]Patients with coronary, peripheral, cerebrovascular disease or diabetes with end-organ damage733 centres in 40 countriesTelmisartanRamipril or ramipril + telmisartan^c^5677662819011250151366903775NROPTIMAAL (2002) \[[@CR43]\]Patients with acute myocardial infarction and heart failure329 centres in 7 European countriesLosartanCaptopril3569672721213045168NR36617100NRORIENT (2011) \[[@CR44]\]Patients with diabetes mellitus with proteinuriaCentres in Japan and Hong KongOlmesartanPlacebo38695925208NRNRNR7510041005100PRoFESS (2008) \[[@CR45]\]Patients with a recent ischaemic stroke695 centres in 35 countriesTelmisartanPlacebo30646627NRNRNRNR4374328NRNRRENAAL (2001) \[[@CR46]\]Patients with diabetes and nephropathy250 centres in 28 countriesLosartanPlacebo41636030228142452198293010011100ROAD (2007) \[[@CR47]\]Patients with proteinuria and chronic renal insufficiencyNanfang Hospital Renal Division in ChinaLosartanBenazepril4463502397NRNR177NR63000100SCAST (2011) \[[@CR48]\]Patients with acute stroke146 centres in EuropeCandesartanPlacebo65871NRNRNRNRNRNR70NR16NRNRSCOPE (2003) \[[@CR49]\]Patients with mild to moderate elevated blood pressure527 centres in EuropeCandesartanPlacebo45367627239NRNRNR9152NR124NRSUPPORT (2015) \[[@CR50]\]Patients with hypertension and CHF17 centres in Tohoku, JapanOlmesartanNon-ARB therapy53756625NR108NRNRNR10010050470Suzuki et al. (2008) \[[@CR51]\]Patients with kidney failure treated with haemodialysis5 dialysis centres in Saitama, JapanLosartan, candesartan, or valsartanNon-ARB therapy36596021157NRNRNR789316522100Takahashi et al. (2006) \[[@CR52]\]Patients with kidney failure treated with haemodialysisEnshu General Hospital in JapanCandesartanNothing19586120NRNRNRNRNR810330100TRANSCEND (2008) \[[@CR53]\]Patients with coronary, peripheral, cerebrovascular disease or diabetes with end-organ damage, and intolerant to ACE inhibitors630 centres in 40 countriesTelmisartanPlacebo5657672819711749158477603674NRT-VENTURE (2009) \[[@CR54]\]Patients with acute myocardial infarction4 centres in JapanValsartanACE inhibitor therapy68363NRNRNRNRNR4057034100NRVal-HeFT (2001) \[[@CR55]\]Patients with heart failure302 centres in 16 countriesValsartanPlacebo238063NRNRNRNRNRNRNR1002557NRVALIANT (2003) \[[@CR56]\]Patients with recent myocardial infarction and LVEF \< 35%931 centres in 24 countriesValsartanCaptopril^d^25786527NRNRNRNRNR561523100NRVALUE (2004) \[[@CR6]\]Patients with hypertension and high risk of cardiac eventCentres in 31 countriesValsartanAmlodipine50586729NRNRNRNRNR936NR45NR*ACE* Angiotensin-converting enzyme, *ARB* Angiotensin II receptor blockers, *CHF* Congestive heart failure, *IHD* Ischaemic heart disease, *LVEF* Left-ventricular ejection fraction, *NR* Not reported^a^IDNT (2003): Two control groups, placebo group was excluded^b^IRMA-2 (2001): Two intervention groups, irbesartan 150 mg daily and irbesartan 300 mg daily were combined^c^ONTARGET (2008): Three intervention groups, ramipril + telmisartan group was excluded^d^VALIANT (2003) Three intervention groups, valsartan + captopril group was excluded

Quantitative synthesis {#Sec8}
----------------------

After pooling all the available evidence, it was found that ARBs do not increase the risk of all-cause mortality (RR 1.00; 95%CI 0.97--1.04), myocardial infarction (RR 1.01; 95%CI 0.96--1.06), or stroke (RR 0.92; 95%CI 0.83--1.01) (Fig. [2](#Fig2){ref-type="fig"}). Sensitivity analyses based on different study and participants characteristics showed no increase in risk of any of the three outcomes of interest. However, it was also noticed that ARBs did not reduce the risk of all-cause mortality (RR 0.99; 95%CI 0.95--1.04) or myocardial infarction (RR 0.96; 95%CI 0.88--1.05) when compared to placebo, ARBs only decreased the risk of stroke (RR 0.91; 95%CI 0.85--0.98) (Table [2](#Tab2){ref-type="table"}). Sensitivity analyses also revealed a decreased in all-cause mortality risk with ARBs when the proportion of smokers is small (\< 25%) (RR 0.91; 95%CI 0.84--0.98); and stroke in females (RR 0.76; 95%CI 0.68--0.84), patients with elevated total cholesterol (RR 0.82; 95%CI 0.82--0.91) and lower levels of HDL (RR 0.90; 95%CI 0.80--0.98) (Table [2](#Tab2){ref-type="table"}). Fig. 2Forest plot depicting the relative risk of ARBs on a) all-cause mortality, b) myocardial infarction, and c) strokeTable 2Sensitivity analysesAll-cause mortalityMyocardial infarctionStrokeRR (95%CI)*I*^2^NRR (95%CI)*I*^2^NRR (95%CI)*I*^2^NType of control Placebo0.99 (0.95--1.04)13180.96 (0.88--1.05)014**0.91 (0.85--0.98)**714 Active1.01 (0.95--1.08)28211.03 (0.96--1.11)7230.93 (0.79--1.08)5422 Active only ACE inhibitors1.04 (0.95--1.13)4681.01 (0.93--1.09)090.98 (0.88--1.10)08Follow-up period ≤ 40 weeks1.01 (0.91--1.14)51190.98 (0.88--1.10)12180.94 (0.74--1.20)4018 \> 40 weeks1.00 (0.96--1.03)0201.03 (0.96--1.10)0190.90 (0.82--1.00)4518Proportion of males ≤ 50%0.93 (0.86--1.00)061.02 (0.85--1.22)375**0.76 (0.68--0.84)**05 \> 50%1.02 (0.97--1.06)23331.01 (0.95--1.07)0320.96 (0.87--1.05)2831Age ≤ 65 years0.98 (0.88--1.09)32180.95 (0.85--1.06)0151.03 (0.80--1.34)2212 \> 65 years1.01 (0.98--1.05)10201.04 (0.98--1.10)0210.92 (0.84--1.00)4123BMI Normal range0.84 (0.60--1.19)3170.81 (0.41--1.57)061.21 (0.77--1.90)05 Overweight and obese1.01 (0.98--1.04)0241.01 (0.96--1.07)5240.92 (0.83--1.01)4923Elevated total cholesterol ≥ 200 mg/dL0.98 (0.91--1.05)15100.99 (0.91--1.08)08**0.82 (0.74--0.91)**67Elevated LDL ≥ 120 mg/dL1.01 (0.90--1.14)3670.97 (0.87--1.07)060.86 (0.70--1.07)455Decreased HDL \< 50 mg/dL1.01 (0.95--1.08)15110.99 (0.89--1.09)2010**0.90 (0.82--0.98)**08Elevated triglyceride ≥ 150 mg/dL1.01 (0.94--1.08)1380.99 (0.90--1.09)1680.92 (0.83--1.01)07Proportion of smokers \< 25%**0.91 (0.84--0.98)**2120.99 (0.88--1.11)0130.81 (0.67--0.99)4112 ≥ 25%0.99 (0.95--1.05)7150.99 (0.91--1.01)0120.92 (0.87--0.98)012Hypertension Only patients with hypertension0.98 (0.89--1.07)0121.02 (0.80--1.29)27120.82 (0.66--1.03)5713Chronic heart failure (CHF) Only patients without CHF0.97 (0.92--1.03)0110.99 (0.83--1.18)43120.85 (0.73--1.00)4711 Only patients with CHF1.00 (0.85--1.19)7561.06 (0.86--1.32)081.04 (0.81--1.32)148Diabetes mellitus (DM) Only patients without DM0.99 (0.38--2.61)020.65 (0.26--1.59)4830.72 (0.50--1.04)373 Only patients with DM1.04 (0.88--1.23)070.99 (0.53--1.80)6741.31 (0.73--2.35)303Ischemic/coronary artery disease Only patients with ischemic/coronary artery disease1.06 (0.91--1.22)2570.97 (0.88--1.07)071.02 (0.84--1.24)05Chronic kidney disease Only patients with chronic kidney disease0.86 (0.66--1.12)5080.99 (0.71--1.41)2091.08 (0.83--1.39)08*CI* confidence interval; *N* number of studies; *RR* relative risk; *ACE* angiotensin-converting-enzymeStatistically significant results are emboldened

The most common deficiencies were no blinding of participants and personnel (*n* = 14; 31%), followed by no blinding of the outcome assessor (*n* = 10; 22%) and incomplete outcome data (*n* = 10; 22%). Overall, the RCTs showed low risk of bias except for E-COST \[[@CR25]\], E-COST-R \[[@CR26]\], and Kondo et al. \[[@CR36]\] ([S2](#MOESM1){ref-type="media"}).

The Doi plots revealed minor asymmetry for all-cause mortality (*LFK* index = − 1.24) and myocardial infarction (*LFK* index = − 1.33) for RCTs reporting favourable results for ARBs. No asymmetry was observed for stroke ([supplementary material S3](#MOESM1){ref-type="media"}).

Discussion {#Sec9}
==========

Findings from previous RCTs were controversial, the VALUE \[[@CR6]\] and the CHARM-alternative \[[@CR7]\] trials found increase in myocardial infarction with ARBs compared to amlodipine and placebo, respectively. While other large RCTs such as the LIFE \[[@CR38]\] and the RENAAL \[[@CR46]\] trials found a decrease in all-cause of death and myocardial infarction with ARBs. In 2011, Bangalore et al. \[[@CR57]\] conducted a meta-analysis on ARBs and the risk of myocardial infarction and found that ARBs do not increase the risk of cardiovascular events. Since then, multiple RCTs have been published; in our meta-analysis we pooled the most updated evidence (45 RCTs comprising of 170,794 participants -- 8 RCTs and 23,000 more participants that Bangalore et al.) and corroborated that ARBs are safe medications as they do not increase the risk of all-cause mortality, myocardial infarction, or stroke. It is worth pointing out that our meta-analysis (in line with previous studies \[[@CR57], [@CR58]\]) also found that ARBs do not reduce the risk of all-cause mortality and myocardial infarction when compared to placebo.

In addition, the safety profile of ARBs was examined in multiple scenarios by restricting the analysis to different study and participants characteristics (i.e. sensitivity analyses). In none of the cases, ARBs were found to increase the risk of all-cause mortality, myocardial infarction, and stroke. ARBs reduce the risk of all-cause mortality by 9% in populations with low prevalence of smokers and exerts a cerebrovascular protective effect in female patients and patients with abnormal total cholesterol or HDL.

Findings from our study are reassuring for patients and clinicians as ARBs are widely used to treat conditions such as hypertension, chronic kidney disease/kidney failure (especially in patients with diabetes mellitus), and heart failure. However, the findings need to be understood in light of some of the limitations. Only RCTs were included, but the possibility of confounding not accounted during the analysis of the RCTs cannot be completely ruled out. There was heterogeneity in the RCTs protocols (e.g. inclusion criteria, different ARBs, different doses, follow-up) that needs to be accounted in future research synthesis studies through individual patients meta-analysis.

Conclusion {#Sec10}
==========

In conclusion, our meta-analysis provides reassuring evidence for patients and clinicians that ARBs are safe drugs, and do not increase the risk of death, myocardial infarction, and stroke.
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